274 related articles for article (PubMed ID: 25572799)
21. Recipient/donor HLA and CMV matching in recipients of T-cell-depleted unrelated donor haematopoietic cell transplants.
Shaw BE; Mayor NP; Szydlo RM; Bultitude WP; Anthias C; Kirkland K; Perry J; Clark A; Mackinnon S; Marks DI; Pagliuca A; Potter MN; Russell NH; Thomson K; Madrigal JA; Marsh SGE
Bone Marrow Transplant; 2017 May; 52(5):717-725. PubMed ID: 28092349
[TBL] [Abstract][Full Text] [Related]
22. High risk of cytomegalovirus infection following solid organ transplantation despite prophylactic therapy.
Harvala H; Stewart C; Muller K; Burns S; Marson L; MacGilchrist A; Johannessen I
J Med Virol; 2013 May; 85(5):893-8. PubMed ID: 23508914
[TBL] [Abstract][Full Text] [Related]
23. Impact of human leukocyte antigen mismatch on lung transplant outcome.
Yamada Y; Langner T; Inci I; Benden C; Schuurmans M; Weder W; Jungraithmayr W
Interact Cardiovasc Thorac Surg; 2018 May; 26(5):859-864. PubMed ID: 29300898
[TBL] [Abstract][Full Text] [Related]
24. Detection of human leukocyte antigen compatibility and antibodies in liver transplantation in China.
Meng XQ; Zhang X; Fan J; Zhou L; Hao B; Chen XM; Ma WH; Zheng SS
Hepatobiliary Pancreat Dis Int; 2009 Apr; 8(2):141-5. PubMed ID: 19357026
[TBL] [Abstract][Full Text] [Related]
25. Cytomegalovirus infection and donor/recipient HLA antigens: interdependent co-factors in pathogenesis of vanishing bile-duct syndrome after liver transplantation.
O'Grady JG; Alexander GJ; Sutherland S; Donaldson PT; Harvey F; Portmann B; Calne RY; Williams R
Lancet; 1988 Aug; 2(8606):302-5. PubMed ID: 2899720
[TBL] [Abstract][Full Text] [Related]
26. Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy.
George B; Pati N; Gilroy N; Ratnamohan M; Huang G; Kerridge I; Hertzberg M; Gottlieb D; Bradstock K
Transpl Infect Dis; 2010 Aug; 12(4):322-9. PubMed ID: 20487414
[TBL] [Abstract][Full Text] [Related]
27. Primary Cytomegalovirus Infection in Seronegative Kidney Transplant Patients Is Associated with Protracted Cold Ischemic Time of Seropositive Donor Organs.
Schlott F; Steubl D; Hoffmann D; Matevossian E; Lutz J; Heemann U; Hösel V; Busch DH; Renders L; Neuenhahn M
PLoS One; 2017; 12(1):e0171035. PubMed ID: 28129395
[TBL] [Abstract][Full Text] [Related]
28. Prophylactic ganciclovir is more effective in HLA-identical family member marrow transplant recipients than in more heavily immune-suppressed HLA-identical unrelated donor marrow transplant recipients. Australasian Bone Marrow Transplant Study Group.
Atkinson K; Arthur C; Bradstock K; Dale B; Downs K; Gibson J; Golenia M; Ho J; Joshua D; Juttner C
Bone Marrow Transplant; 1995 Sep; 16(3):401-5. PubMed ID: 8535313
[TBL] [Abstract][Full Text] [Related]
29. Pre-transplant assessment of CMV-specific immune response by Elispot assay in kidney transplant recipients.
Rittà M; Costa C; Sidoti F; Ballocco C; Ranghino A; Messina M; Biancone L; Cavallo R
New Microbiol; 2015 Jul; 38(3):329-35. PubMed ID: 26147141
[TBL] [Abstract][Full Text] [Related]
30. Valganciclovir administration to kidney donors to reduce the burden of cytomegalovirus and Epstein-Barr virus transmission during transplantation.
Verghese PS; Schmeling DO; Knight JA; Matas AJ; Balfour HH
Transplantation; 2015 Jun; 99(6):1186-91. PubMed ID: 25489844
[TBL] [Abstract][Full Text] [Related]
31. An assessment of donor-to-recipient transmission patterns of human cytomegalovirus by analysis of viral genomic variants.
Manuel O; Pang XL; Humar A; Kumar D; Doucette K; Preiksaitis JK
J Infect Dis; 2009 Jun; 199(11):1621-8. PubMed ID: 19385736
[TBL] [Abstract][Full Text] [Related]
32. Long-term outcome of human leukocyte antigen mismatching in liver transplantation: results of the National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database.
Balan V; Ruppert K; Demetris AJ; Ledneva T; Duquesnoy RJ; Detre KM; Wei YL; Rakela J; Schafer DF; Roberts JP; Everhart JE; Wiesner RH
Hepatology; 2008 Sep; 48(3):878-88. PubMed ID: 18752327
[TBL] [Abstract][Full Text] [Related]
33. Tetramer monitoring to assess risk factors for recurrent cytomegalovirus reactivation and reconstitution of antiviral immunity post allogeneic hematopoietic stem cell transplantation.
Borchers S; Luther S; Lips U; Hahn N; Kontsendorn J; Stadler M; Buchholz S; Diedrich H; Eder M; Koehl U; Ganser A; Mischak-Weissinger E
Transpl Infect Dis; 2011 Jun; 13(3):222-36. PubMed ID: 21585633
[TBL] [Abstract][Full Text] [Related]
34. Cytomegalovirus infection in renal transplant recipients: one center's experience.
Bal Z; Uyar ME; Tutal E; Erdogan E; Colak T; Sezer S; Haberal M
Transplant Proc; 2013; 45(10):3520-3. PubMed ID: 24314948
[TBL] [Abstract][Full Text] [Related]
35. Impact of valganciclovir prophylaxis on the development of severe late-cytomegalovirus disease in high-risk solid organ transplant recipients.
Cervera C; Pineda M; Linares L; Marcos MA; Esteva C; Antón A; Cofán F; Ricart MJ; Navasa M; Pérez-Villa F; Pumarola T; Moreno A
Transplant Proc; 2007 Sep; 39(7):2228-30. PubMed ID: 17889146
[TBL] [Abstract][Full Text] [Related]
36. Impact of cytomegalovirus immunodominant HLA-I donor-recipient matching on the incidence and features of virus DNAemia and virus-specific T-cell immune reconstitution in unmanipulated haploidentical hematopoietic stem cell transplantation.
Huntley D; Giménez E; Vázquez L; Pascual MJ; Amat P; Remigia MJ; Hernández-Boluda JC; García M; Gago B; Torres I; de la Asunción CS; Hernani R; Pérez A; Albert E; Piñana JL; Solano C; Navarro D
Transpl Infect Dis; 2023 Jun; 25(3):e14065. PubMed ID: 37120821
[TBL] [Abstract][Full Text] [Related]
37. Factors associated with the development of cytomegalovirus infection following solid organ transplantation.
da Cunha-Bang C; Sørensen SS; Iversen M; Sengeløv H; Hillingsø JG; Rasmussen A; Mortensen SA; Fox ZV; Kirkby NS; Christiansen CB; Lundgren JD
Scand J Infect Dis; 2011 May; 43(5):360-5. PubMed ID: 21306196
[TBL] [Abstract][Full Text] [Related]
38. Pre-transplant cytomegalovirus immunoglobulin G antibody levels could prevent severe cytomegalovirus infections post-transplant in liver transplant recipients: Experience from a tertiary care liver centre.
Gupta E; Pamecha V; Verma Y; Kumar N; Rastogi A; Hasnian N; Bhadoria AS
Indian J Med Microbiol; 2017; 35(4):499-503. PubMed ID: 29405140
[TBL] [Abstract][Full Text] [Related]
39. CMV seronegative donors: Effect on clinical severity of CMV infection and reconstitution of CMV-specific immunity.
van der Heiden PLJ; van Egmond HM; Veld SAJ; van de Meent M; Eefting M; de Wreede LC; Halkes CJM; Falkenburg JHF; Marijt WAF; Jedema I
Transpl Immunol; 2018 Aug; 49():54-58. PubMed ID: 29679650
[TBL] [Abstract][Full Text] [Related]
40. Predictive factors for cytomegalovirus infection after orthotopic liver transplantation using an ultrasensitive polymerase chain reaction assay.
Basse G; Esposito L; Mengelle C; Kamar N; Ribes D; Lavayssière L; Pillet A; Suc B; Barange K; Rostaing L
Transplant Proc; 2006 Sep; 38(7):2339-41. PubMed ID: 16980084
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
